April 1, 2020 | Deemed an essential industry across the globe, the Pharmaceutical-Biotech Industry
has generally been allowed to keep the majority of its plants operating. Companies are still working out the remote aspect for those employees who can work offsite, while in many cases others are expanding production to 24/7 operations to keep up with demand.
The same holds true for active capital construction projects. Or does it? Questions and quandaries have popped up across the U.S. on job sites. Do local sanctions supersede protected status when it comes to construction? If a project is underway, can it continue? Can a new one start? Are manufacturing capacity projects allowed, but new labs halted? General contractors and subs alike are in the dark with no firm written guidelines or rules across the board. It lays in individual interpretation in most cases. Not to mention contractual agreements and liability.
For some, it appears to be business as usual. In other cases, the general contractor decides to proceed, but wonders if the subs will show up? Can the building supplies be delivered?
These questions and more will continue to crop up as the COVID-19 crisis continues to evolve and regulations are developed.
In the meantime, it is important to keep in mind that Pharma-Bio Industry projects tend to have a high probability factor for making it off the white board to active construction. Obviously, some timelines may be delayed, but in all likelihood, most projects that are stalled will eventually launch or resume active construction....
April 1, 2020 | Mexico's Communications and Transport Ministry will not suspend port operations
despite the COVID-19 contingency plan entering Stage Two on March 22. However, the ministry will adopt sanitary measures and international recommendations to prevent the spread of the virus through maritime transport.
The ministry has not announced recent suspensions or cancellation of works on port expansion projects in the 2020-24 national infrastructure program. Industrial Info is tracking more than 280 active projects at Mexican ports and private terminals worth $4.5 billion. Click here
for a list....
March 26, 2020 | "Donate" and "drug companies
" are not often found in the same sentence. But, in this case, it is true, as several companies have offered up staggering amounts of the drug chloroquine (and other variations), a malaria drug developed in the 1930s, pending approvals on its effectiveness in combating the COVID-19 global scourge.
Amneal, Bayer, Novartis, Mylan and Teva are among those pledging hundreds of millions of doses of the drug, which is not currently approved as a treatment for COVID-19, to governments and hospitals. That has not stopped the field use of the drug by desperate physicians and the launch of scores of clinical trials across the world. Anecdotal results have been promising, but firm dosing guidelines and projected outcomes have not yet been established.
There has been a run on the drug in pharmacies across the world as scores of people secured prescriptions for its off-label use. New restrictions have popped up to safeguard the existing supply for testing and monitored use....